Showing 2281-2290 of 4063 results for "".
- AcuFocus Receives FDA Approval for the IC-8 Apthera IOL, the First and Only Small Aperture Lenshttps://modernod.com/news/acufocus-announces-fda-approval-for-the-ic-8-apthera-iol-the-first-and-only-small-aperture-lens-for-cataract-surgery/2480986/AcuFocus has received FDA approval for its IC-8 Apthera IOL, the first and only non-toric extended depth-of-focus IOL approved for the 82% of cataract patients who have as much as 1.5 diopters (D) of corneal astigmatism.2 “We are delighted to receive
- SIFI Announces EMA Validation of its Marketing Authorization Application for Akantior for the Treatment of Acanthamoeba Keratitishttps://modernod.com/news/sifi-announces-ema-validation-of-its-marketing-authorization-application-for-akantior-for-the-treatment-of-acanthamoeba-keratitis/2480899/SIFI announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for Akantior (polihexanide) for the treatment of acanthamoeba keratitis (AK). Today's announcement follows the company’s announcement in October 2
- AGTC Announces Positive 3-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosahttps://modernod.com/news/agtc-announces-positive-3-month-interim-results-from-skyline-trial-of-agtc-501-for-the-treatment-of-x-linked-retinitis-pigmentosa/2480865/Applied Genetic Technologies Corporation (AGTC) reported positive 3-month interim data from its ongoing phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP).
- Heidelberg Engineering Presents Various Scientific Innovations at ARVOhttps://modernod.com/news/heidelberg-engineering-presents-various-scientific-innovations-at-arvo/2480819/Heidelberg Engineering showcases its research capabilities at this year’s ARVO congress that takes place in Denver, Colorado, USA, from May 1–4. The team looks forward to reconnecting with the global research community after 2 years of solely virtual ARVO meetings, and to demonstratin
- Orasis Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopiahttps://modernod.com/news/orasis-announces-positive-phase-3-topline-results-of-novel-eye-drop-candidate-csf-1-for-the-treatment-of-presbyopia/2480784/Orasis Pharmaceuticals announced that the phase 3 NEAR-1 and NEAR-2 clinical trials, which evaluated the efficacy and safety of CSF-1, its novel eye drop candidate, met their primary and key secondary endpoints. Additional details of these trials will be presented at future medical meet
- ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategyhttps://modernod.com/news/proqr-announces-additional-sepofarsen-illuminate-trial-analyses-and-provides-update-on-company-strategy/2480765/ProQR Therapeutics provided an update on its sepofarsen program following a comprehensive post-hoc analysis of the data from the phase 2/3 Illuminate trial in people with CEP290-mediated Lebercongenital amaurosis 10, or LCA10, a
- Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidatehttps://modernod.com/news/orasis-pharmaceuticals-concludes-phase-3-clinical-trials-for-presbyopia-candidate/2480699/Orasis Pharmaceuticals announced the completion of its NEAR-1 and NEAR-2 phase 3 clinical studies. “Orasis is committed to reshaping vision possibilities by developing a presbyopia eye drop with the patient in mind,” said Elad Kedar, Chief Executive Officer of Orasis. &ldquo
- Prevent Blindness to Hold 17th Annual “Eyes on Capitol Hill” Advocacy Eventhttps://modernod.com/news/prevent-blindness-to-hold-17th-annual-eyes-on-capitol-hill-advocacy-event/2480666/Prevent Blindness will be holding its 17th annual Eyes on Capitol Hill advocacy day as a virtual event on March 1-2, 2022. Continuing its mission as a patient advocacy group, Prevent Blindness created the Eyes on Capitol Hill program specifically to provide patients, caregivers, al
- Novartis Presents Positive Results From Three Phase 3 Trials of Beovu in DMEhttps://modernod.com/news/novartis-presented-positive-results-from-three-phase-3-trials-of-beovu-in-dme/2480638/At the Angiogenesis, Exudation, and Degeneration 2022 Virtual Meeting, Novartis presented additional positive results from three phase 3 trials of Beovu in DME, including results from patients dosed at up to 16-week intervals. This was the first detailed presentation of the year 2 results&nb
- Nanoscope Therapeutics Announces FDA Clearance of IND for MCO-010 Gene Therapy in Stargardt Macular Degeneration Patientshttps://modernod.com/news/nanoscope-therapeutics-announces-fda-clearance-of-ind-for-mco-010-gene-therapy-in-stargardt-macular-degeneration-patients/2480594/Nanoscope Therapeutics announced it received IND clearance from the FDA to begin a phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy to restore vision in Stargardt patients. “This is another important milestone for Nanoscop